Login to Your Account



Second Look at Trial Data

Acorda Staggers on FDA Word: MS Drug's Walk Data Below Par

By Donna Young


Monday, October 12, 2009
Acorda Therapeutics Inc.'s stock plunged 21.4 percent after FDA drug reviewers raised concerns in briefing documents about the efficacy of Amaya (fampridine sustained-release) in improving the walking ability in patients with multiple sclerosis. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription